Genetesis
Manufacturing · Ohio, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5412 Courseview Dr Ste 150, Mason, Ohio,...Phone Number
(513) 715-5045Website
www.genetesis.comRevenue
$7.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Genetesis
Genetesis is a healthcare company that has developed the CardioFlux Membership program, aimed at transforming preventive cardiac care and addressing heart disease. Their flagship product, CardioFlux, utilizes magnetocardiography to detect functionally significant ischemia quickly and non-invasively. The company targets patients experiencing chest pain and healthcare professionals seeking efficient diagnostic solutions. With a focus on improving hospital workflows and reducing patient wait times, Genetesis is committed to enhancing the standard of care in cardiac imaging.Explore more
Genetesis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genetesis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Genetesis is spiking on competitors!
Product Launch: Get notified when Genetesis launches new products
Genetesis, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Genetesis had a recent Job posting/layoffs
Check if Genetesis has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Genetesis
Funding: Get notified immidiatlly once Genetesis has new funding data
Earning: See what the market has to say on Genetesis recently announced quarterly report
Recommended Actions
Find VP level buyers at Genetesis
Find 3 more new buyers
Compare Similar Companies to Genetesis
Compare insights from companies similar to Genetesis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Genetesis
$7.5M
11-50
Private
$35.9M
2013
RS
Robert SokolowskiVice President, Clinical, Quality & Regulatory Affairs
Company Profile Activity
Activity Insights
Genetesis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Genetesis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Genetesis.
Genetesis financials insights
Gather financial insights about Genetesis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Angel/Seed
$1.2M
2018
Series A
$7.5M
2020
Series B
$9.2M
2021
Debt
$508K
2022
Series C
$17.5M
Genetesis Tech Stack
A closer look at the technologies used by Genetesis
Most Recent Scoops
Person-Based
Asset Management, Personnel Moves
Person-Based
Funding, Acquisitions, Finance
New Hire
Executive Move
New Hire
Executive Move
New Hire
Executive Move
Genetesis News & Media
Health Canada Approves CardioFlux MCG for the Diagnosis of Myocardial Ischemia
Newly announced Canadian license marks the first approval of any kind of MCG device in Health Canada history MASON, Ohio, Sept. 20, 2024 /PRNewswire/ -- Genetesis, Inc., a leader in the field of magnetocardiography (MCG), today announced that Health Canada has approved the CardioFlux...Genetesis Formally Launches MICRO2 Trial with Announcement of First Patient Enrollment
MICRO2 aims to build upon early evidence demonstrating MCG's ability to aid in the noninvasive diagnosis of Coronary Microvascular Dysfunction MASON, Ohio, July 3, 2024 /PRNewswire/ -- Genetesis, Inc., a leader in the field of magnetocardiography (MCG), today announced the formal launch...Genetesis Announces Formal Publication of Results from the MAGNETO Trial
MASON, Ohio--(BUSINESS WIRE)--Genetesis, Inc., a leader in the field of magnetocardiography (MCG), today announced that official results from its MAGNETO trial were published in a special issue of the American Heart Journal Plus: Cardiology Research and Practice. The results of MAGNETO demonstrate MCG’s ability to identify myocardial ischemia in low-to-intermediate risk patients presenting to the emergency department (ED) with acute chest pain and validate MCG’s performance compared to tests thGenetesis Receives 2nd FDA Breakthrough Device Designation for Non-Invasive Diagnosis of Myocardial Ischemia Using CardioFlux MCG
MASON, Ohio--(BUSINESS WIRE)--Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its flagship imaging solution, CardioFlux MCG, to identify myocardial ischemia in patients who may be suffering from coronary microvascular disease (CMD). Historically, CMD has been hard to identify in clinical practice due to a lack of effective functional diagnostics with
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genetesis
Sign Up For FreeTo access detailed company insights
Genetesis is a healthcare company that has developed the CardioFlux Membership program, aimed at transforming preventive cardiac care and addressing heart disease. Their flagship product, CardioFlux, utilizes magnetocardiography to detect functionally significant ischemia quickly and non-invasively. The company targets patients experiencing chest p... Read More
